Objective: To investigate the clinical efficacy of two different inhalation regimens for the treatment of pediatric bronchopneumonia. Methods: A total of 156 children with bronchopneumonia admitted to our hospital from October 2022 to October 2024 were analyzed and divided into two groups by lottery. The control group was treated with budesonide suspension, while the observation group was combined with ipratropium bromide inhalation solution. The improvement time of clinical symptoms, treatment effect, inflammatory and adverse reaction incidence rates and other indicators of the two groups of children were compared.Results: The improvement time of symptoms in the observation group was shortened, and the treatment effect was higher than that in the control group. The inflammatory factors of patients in the observation group were reduced(P＜0.05)； And the occurrence of adverse reactions in the two groups was similar(P＞0.05)。Conclusion: The treatment of pediatric bronchopneumonia with compressed nebulized budesonide suspension combined with ipratropium bromide inhalation solution can effectively improve clinical symptoms, with high safety and few adverse reactions.